Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Gurjeet Kahlon

Geriatric Medicine Centerville, OH Medical Doctor

NPI 1649209644 CMS profile 74847

6611 Clyo Rd, Suite E, Centerville, OH 45459

Open in the dashboard

General payments

$7,501

513 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Gurjeet Kahlon of Centerville, OH is reported in the CMS Open Payments database as having received $7,501 across 513 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 94th percentile of Geriatric Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,050 54
2024 General $922 76
2023 General $1,263 84
2022 General $996 77
2021 General $1,305 78
2020 General $1,025 74
2019 General $940 70

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Gurjeet Kahlon
  • Geriatric Medicine median
  • Middle half of Geriatric Medicine
  • National median

In program year 2025, general payments to Gurjeet Kahlon were reported at $1,050. Among 1,028 Geriatric Medicine profiles paid that year, the median was $123 and the middle half received between $35 and $408.

Show as a table
Year Gurjeet Kahlon Geriatric Medicine median Middle half National median
2019 $940 $122 $40–$435 $163
2020 $1,025 $98 $25–$349 $114
2021 $1,305 $125 $34–$441 $132
2022 $996 $124 $36–$408 $149
2023 $1,263 $121 $41–$383 $160
2024 $922 $134 $41–$435 $164
2025 $1,050 $123 $35–$408 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Janssen Pharmaceuticals, Inc $1,136 117 payments
  2. Bayer HealthCare Pharmaceuticals Inc. $772 79 payments
  3. Lilly USA, LLC $494 38 payments
  4. AbbVie, Inc. $483 30 payments
  5. Astellas Pharma US Inc $399 15 payments
  6. Amgen Inc. $326 18 payments
  7. Pfizer Inc. $324 23 payments
  8. Allergan Inc. $320 20 payments
  9. AstraZeneca Pharmaceuticals LP $308 19 payments
  10. Novartis Pharmaceuticals Corporation $279 17 payments
  11. Other $2,660 137 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $7,257 510 payments
  2. Education $244 3 payments
Products named General payments · program years 2019–2025
  1. XARELTO $1,136 117 payments
  2. Kerendia $772 79 payments
  3. VRAYLAR $360 18 payments
  4. INVOKANA $266 41 payments
  5. ENTRESTO $245 15 payments
  6. QULIPTA $212 11 payments
  7. ELIQUIS $190 15 payments
  8. JARDIANCE $187 12 payments
  9. EVENITY $184 11 payments
  10. FreeStyle Libre 2 $161 2 payments
  11. Other $4,880 298 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 232 drugs

Part D claims

19,086

Median for Internal Medicine: 777

Drug cost

$1,316,188

Median for Internal Medicine: $73,373

Branded share of claims

20.7%

Median for Internal Medicine: 19.3%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Eliquis Apixaban Brand 632 $220,729
Ingrezza Valbenazine Tosylate Brand 29 $110,063
Jardiance Empagliflozin Brand 122 $62,373
Xarelto Rivaroxaban Brand 205 $55,848
Trulicity Dulaglutide Brand 59 $51,938
Abilify Maintena Aripiprazole Brand 18 $44,743
Xifaxan Rifaximin Brand 31 $44,044
Austedo Deutetrabenazine Brand 21 $42,517
Januvia Sitagliptin Phosphate Brand 127 $37,355
Creon Lipase/Protease/Amylase Brand 51 $26,580

The 10 drugs with the highest cost, of 232 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 104,182 Part D prescribers listed as Internal Medicine; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 35 billing codes

Paid by Medicare

$96,199

Of which drugs: $1,150

Medicare patients

236

Average age 79

Services billed

1,277

134 women, 102 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 61%
Chronic kidney disease 58%
Depression 55%
Diabetes 47%
Heart failure 47%
Ischemic heart disease 47%
Alzheimer's or dementia 42%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Vaccine for influenza for injection into muscle 90653 Office 11 11 $867

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 21 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
Kerendia
  • Bayer HealthCare Pharmaceuticals Inc. $141
$141 17 —
Leqembi
  • Eisai Inc. $93
$93 — —
JARDIANCE
  • Lilly USA, LLC $71
  • Boehringer Ingelheim Pharmaceuticals, Inc. $13
$84 122 —
MOUNJARO
  • Lilly USA, LLC $68
$68 — —
YUPELRI
  • Mylan Specialty L.P. $60
$60 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 21 in the dashboard with a free account

Records

513 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Geriatric Medicine in Ohio

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record